Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1

F. J. Gifford*, J. R. Morling, J. A. Fallowfield

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)

Abstract

Background: Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment. Aim: To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs). Methods: MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for RCTs reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search terms included: ‘hepatorenal syndrome’, ‘terlipressin’, ‘noradrenaline’, ‘octreotide’, ‘midodrine’, ‘vasopressin’, ‘dopamine’, ‘albumin’ and synonyms. Comparison of vasoactive drugs vs. placebo/no treatment, and two active drugs were included. Meta-analysis was performed for HRS1 reversal, creatinine improvement, mortality and adverse events. Results: Twelve RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin led to HRS1 reversal more frequently than albumin alone or placebo (RR: 2.54, 95% CI: 1.51–4.26). Noradrenaline was effective in reversing HRS1, but trials were small and nonblinded. Overall, there was mortality benefit with terlipressin (RR: 0.79, 95% CI: 0.63–1.01), but sensitivity analysis including only trials with low risk of selection bias weakened this relationship (RR: 0.87, 95% CI: 0.71–1.06). Notably, there was a significant risk of adverse events with terlipressin therapy (RR: 4.32, 95% CI: 0.75–24.86). Conclusions: Terlipressin treatment is superior to placebo for achieving HRS1 reversal, but mortality benefit is less clear. Terlipressin is associated with significant adverse events, but infusion regimens may be better tolerated. There is continued need for safe and effective treatment options for hepatorenal syndrome.

Original languageEnglish
Pages (from-to)593-603
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number5
DOIs
Publication statusPublished - 1 Mar 2017
Externally publishedYes

Bibliographical note

Funding Information:
The authors are grateful to Sharon Tuck (Epidemiology and Statistics Core, Edinburgh Clinical Research Facility) for statistical advice. Declaration of personal interests: JA Fallowfield has served as a speaker, a consultant and an advisory board member for Novartis and as a speaker and consultant for Merck. JA Fallowfield has received research funding from GlaxoSmithKline. Declaration of funding interests: JA Fallowfield is funded by the Scottish Funding Council through a NHS Research Scotland Senior Clinical Fellowship.

Publisher Copyright:
© 2017 John Wiley & Sons Ltd

Fingerprint

Dive into the research topics of 'Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1'. Together they form a unique fingerprint.

Cite this